The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | COALITION: glofitamab + R-CHOP or glofitamab + pola-R-CHP in high-risk DLBCL
Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the rationale and preliminary results of the COALITION study (NCT04914741) evaluating the safety and efficacy of glofitamab plus R-CHOP or glofitamab plus polatuzumab vedotin-R-CHP (pola-R-CHP) in patients with high-risk diffuse large B-cell lymphoma (DLBCL). Early data from the trial shows promising complete remission rates and good tolerability of the combination. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Roche, AbbVie, GenMab, Novartis, Kite, Gilead, Bristol Myers Squibb
Research funding: Roche, Novartis, Gilead, Takeda
